All In Biotech

NDA 218524 · Baxter Hlthcare Corp

Sodium Bicarbonate

Sodium Bicarbonate · Intravenous

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Aug 14, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

446

105 Phase 3, 28 recruiting

FAERS reports

23,575

20,176 serious, 4,325 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 14, 2026.

Sodium bicarbonate injection is an alkalinizing agent indicated: • to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. ( 1.1 ) • to alkalinize the urine in drug poisoning in adult and pediatric patients in cases in which urinary drug elimination is enhanced by urinary alkalinaztion. ( 1.2 ) Limitation of Use Do not use sodium bicarbonate injection in settings where rapid administration of sodium bicarbonate is required, such as cardiac arrest. In such situations use a more concentrated solution. 1.1 Treatment of Clinically Significant Metabolic Acidosis Sodium bicarbonate injection is indicated to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. 1.2 Urinary Alkalization in Drug Poisoning Sodium bicarbonate injection is indicated to alkalinize the urine in drug poisoning in adult and pediatric patients in cases in which urinary drug elimination is enhanced by urinary alkalinaztion. Limitation of Use Do not use sodium bicarbonate injection in settings where rapid administration of sodium bicarbonate is required, such as cardiac arrest. In such situations use a more concentrated solution.

Mechanism: Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 14, 2026 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabel
1 products under this application
  • SODIUM BICARBONATE · SODIUM BICARBONATE 150MEQ/1000ML (0.15MEQ/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bicarbonate" as an intervention, any sponsor and status, largest first.

All 446 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • acute kidney injury1,735
  • off label use1,699
  • drug ineffective1,662
  • diarrhoea1,477
  • renal failure1,400
  • nausea1,209
  • anaemia1,137
  • death1,076
  • dyspnoea1,054
  • pain996
  • pneumonia993
  • pyrexia985

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004108
2005144
2006172
2007188
2008230
2009209
2010364
2011703
2012624
2013575
2014831
2015928
20161,330
20171,700
20181,457
20191,522
20201,615
20211,864
20221,940
20231,823
20241,908
20251,948
20261,390

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sodium Bicarbonate (Sodium Bicarbonate)

2024 spending

$567K

Beneficiaries

1,804

8,519 claims

Per beneficiary

$314

$0.25 per unit

View as table
YearSpending
2020$517,768
2021$488,902
2022$610,163
2023$741,810
2024$567,270

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,425 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.